Market experience

Umbilical Cord Blood Stem Cell (UCB) Market Experience

Umbilical Cord Blood Stem Cell (UCB) Market

The application of cord blood stem cells is growing faster than other stem cell techniques because of its efficient and cost-effective treatment process. Cord blood is helping the healthcare industry discover new therapies for chronic disease. The UCB stem cell market is experiencing significant growth due to increasing public awareness and government support.

Umbilical cord blood stem cells are potential stem cells that can be converted into any specific type of cell. The global stem cell market dominates the healthcare industry with its reliable and cost-effective method of treatment with less side effects. The global umbilical cord blood stem cell (UCB) market was worth $ 6.5 billion in 2012 and is expected to reach $ 56.4 billion by 2020, registering a CAGR of 33.4% during the period forecast. Government authorities are supporting cord blood stem cell research and clinical trials, which is currently increasing the interest of healthcare companies in investing in research and commercialization of blood stem cell therapies. cord. This is expected to propel the growth of Umbilical Cord Stem Cell (UCB) market in the near future. Athersys, California Stem Cell Inc. and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding the application of cord blood samples create bias among donors, which significantly influences the umbilical cord blood (UCB) stem cell market.

Access the full summary at:

Intense competition among players in the Umbilical Cord Blood Stem Cell (UCB) market has been observed, with the companies trying to build brand awareness. This therefore forces market players to formulate market-based strategies. The cord blood stem cell is the only type of stem cell that is stored under controlled conditions due to its characteristic of higher cell count. The storage services segment is expected to grow at 33.4% CAGR from 2013 to 2020 in the global stem cell umbilical cord blood (UCB) market.

Key benefits
• This report provides market insights regarding therapies, applications, and storage services in the Cord Blood Stem Cells market.
• Detailed analysis of major factors influencing the growth of UCB Stem Cells market so that companies can make development decisions
• The value chain analysis, Porters’ five strengths, the best investment pockets are analyzed and presented in detail in the report.
• Information on important regulatory and reimbursement issues is provided based on geographic areas so that companies can make strategic decisions
• SWOT analysis and strategic developments included in the report for key players: Advanced Cell Technology, Inc. (US), Athersys, California Stem Cell Inc., Cytori Therapeutics Inc., Mesoblast, Opexa Therapeutics Geron Corporation, Neostem Inc.

Key market segments:

By storage

• Public cord blood banks
• Private cord blood banks
• Public against. Private UCB banks

By technology

• Stem cell transplant
• Autologous transplant
• Allogeneic transplant
• Transplant medicine
• Regenerative medicine
• Others
• Cord blood bank
• Blood transfusion
• Cell genetics

By geography

• UCB market in North America
• UCB market in Europe
• UCB market in Asia-Pacific
• UCB market in ROW

Get a sample PDF brochure at:

Allied Market Research (AMR) is a full-service market research and business consulting arm of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global businesses as well as medium and small businesses with unmatched quality of “market research reports” and “business intelligence solutions”. AMR has a focused vision to provide business information and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.
We have professional relationships with various companies, which helps us extract market data which helps us generate accurate research data tables and confirm the highest accuracy in our market forecast. Each of the data presented in the reports we publish is extracted through primary interviews with senior officials of the main companies in the field concerned. Our secondary data sourcing methodology includes in-depth online and offline research and discussions with industry-savvy professionals and analysts.

Shriram dighe
5933 NE Win Sivers Drive
# 205, Portland, OR 97220
United States
Toll free: + 1-800-792-5285
UK: + 44-845-528-1300
Hong-Kong: + 852-301-84916
India (Pune): + 91-20-66346060
Fax: + 1⟨855⟩550-5975
[email protected]
The Web:

This version was posted on openPR.